Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography

Journal of Pharmaceutical Sciences

Volumn 99, Issue 11, 2010, Pages 4746-4752

  Wang, Xianhuo ^a   Zheng, Hao ^a   Zhu, Zhengyan ^a   Wei, Yuquan ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Clinical pharmacokinetics; Intrapleural infusion; Liposome; Paclitaxel; Plasma; Pleural fluid; UPLC

Indexed keywords

LIPOSOME; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INFUSION; DRUG STABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; PLEURA EFFUSION; PLEURA FLUID; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 78149351098     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22169     Document Type: Article

References (24)

1. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. 1971. Plant antitumor agents VI: The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327.
2. Schiff PB, Fant J, Horwitz SB. 1979. Promotion of microtubule assembly in vitro by Taxol. Nature 277: 665-667.
3. Schiff PB, Horwitz SB. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565.
4. McGuire WP, Rowinsky EK, Rosenheim NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. 1989. Taxol: A unique antineoplasic agent with significant activity in advanced ovarian epithelial neoplasm. Ann Intern Med 111: 273-279.
5. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN. 1991. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805.
6. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN. 1993. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388.
7. Kohler DR, Goldspiel BR. 1994. Paclitaxel (taxol). Pharmacotherapy 14: 3-34.
8. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC. 1989. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640-4647.
9. Rowinsky EK, Donehower RC. 1995. Paclitaxel (Taxol). N Engl J Med 332: 1004-1014.
10. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, VanEcho DA, VonHoff DD, Leyland-Jones B. 1990. Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268.
11. Singla AK, Garg A, Aggarwal D. 2002. Paclitaxel and its formulation. Int J Pharm 235: 179-192.
12. Bartoli MH, Biotard M, Fessi H, Beriel H, Devissaguet JP, Picot F, Puisieux F. 1990. In vitro and in vivo anti-tumoral activity of free and encapsulated taxol. J Microencapsul 7: 191-197.
13. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. 1994. A mixed micellar formulation suitable for the parenteral administration of taxol. Pharm Res 11: 206-212.
14. Sharma D, Chelvi TP, Kaur J, Chakravorty K, De TK, Maitra A, Ralhan R. 1996. Novel taxol formulation: Polyvinylpyrrolidone nanoparticle-encapsulated taxol for drug delivery in cancer therapy. Oncol Res 8: 281-286.
15. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C, Martin FJ. 1991. Sterically-stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464.
16. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
17. Gou W, Johnson JL, Khan S, Ahmad A, Ahmad I. 2005. Paclitaxel quantification in mouse plasma and tissues containing liposome-entrapped paclitaxel by liquid chromatography-tandem mass spectrometry: Application to a pharmacokinetics study. Anal Biochem 336: 213-220.
18. Fetterly GJ, Straubinger RM. 2003. Parmacokinetics of paclitaxel-containing liposomes in rat. AAPS PharmSci 5: 32.
19. Soepenberg O, Sparreboom A, de Jonge MJA, Planting ASTH, de Heus G, Loos WJ, Hartman CM, Bowden C, Verweij J. 2004. Real-time pharmacokinetics guiding clinical decisions: Phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours. Eur J Cancer 40: 681-688.
20. Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. 1993. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85: 388-394.
21. Perng RP, Wu MF, Lin SY, Chen YM, Lin JY, Whang-Peng J. 1997. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions. Anti-Cancer Drugs 8: 565-573.
22. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Jr., Rubin S, Curtin J, Barakat R, Phillips M. 1992. Phase I trial of intraperitoneal taxol: A Gynecoloic Oncology Group study. J Clin Oncol 10: 1485-1491.
23. Rowingsky EK, Donehower RC, Jones RJ, Tucher RW. 1988. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093-4100.
24. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N. 1995. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606.